Supplier
Milart Pharmacy INC
Milart Pharmacy INC was paid $36K by Medicaid between Dec 2021 and Oct 2022, across 5 billing codes. Its largest line is G2023, Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source — 32% of everything it billed.
33Billing provider infoMILART PHARMACY INC
BEVERLY HILLS, CA 90212
BEVERLY HILLS, CA 90212
33aNPI1083728059assigned 08/18/2006
33bProvider typeCompounding Pharmacy
28Total paid$36K
24GClaims1,673
24DCodes billed5
24AFirst – last monthDec 2021 – Oct 2022
Compared with peers
Next to other Compounding Pharmacy providers in California
Rank by total paid#9 of 21
Median peer was paid$6K
This provider vs. median6.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 261 | $7K | |
| 2022 | 1,412 | $30K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 32% | 676 | 404 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 29% | 266 | 182 | $10K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 27% | 417 | 250 | $10K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 8.9% | 294 | 170 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.2% | 20 | 16 | $1K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEVIAN, ARASH (OWNER)